Trikafta combines 3 medications – elexacaftor, ivacaftor and tezacaftor – to treat patients with the most common cystic fibrosis mutation . It targets the defect from specific genetic mutations that cause cystic fibrosis, slowing the progression of the disease.
By binding to different places on CFTR proteins, ELEXACAFTOR and TEZACAFTOR work together to help more CFTR proteins reach the cell surface. Illustrations are ... |
3 июл. 2021 г. · The mechanism of action of Trikafta is illustrated in Figure 1. They target epithelial cells lining all of the tubular organs affected in CF, ... |
TRIKAFTA is a prescription medicine used for the treatment of cystic fibrosis (CF) in people aged 2 years and older who have at least one copy of the F508del ... |
Trikafta is a CFTR modulator that helps defective CFTR proteins work more effectively. Both elexacaftor and tezacaftor work as correctors. They bind to the ... How Trikafta works · Indications · Clinical trials |
Trikafta is a medicine that works by improving the flow of chloride and water in patients with cystic fibrosis who have a certain genetic defect. Trikafta ... |
The CFTR modulator Trikafta (elexacaftor/tezacaftor/ivacaftor) combines the correctors elexacaftor and tezacaftor, which help to fix flaws in the CFTR protein ... |
What is this medicine and how does it work. Elexacaftor and tezacaftor are cystic fibrosis transmembrane conductance regulator (CFTR) correctors that bind to ... |
| Novbeti > |
| Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |